कंपनी का अवलोकन
Cue Biopharma, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to developing a novel class of injectable therapeutics designed to selectively engage and modulate targeted, disease-relevant T cells within the United States. The company functions within the broader Healthcare sector, specifically focusing on the Biotechnology industry, which implies a high degree of research and development intensity and a reliance on successful clinical trials for future commercialization. This entity maintains a market capitalization of $28.60M and generates annual revenue of $27.47M based on trailing twelve-month data, while employing a workforce of 29 individuals. The valuation figures indicate that the company is a small-cap enterprise with a market capitalization of $28.60M that is nearly equivalent to its annual revenue of $27.47M, suggesting a business model where current sales heavily influence market value in the absence of significant profit generation. The relatively small employee count of 29 personnel relative to the revenue stream and market cap highlights a lean organizational structure typical of early-stage biotechnology firms where revenue is often concentrated on specific product candidates rather than diversified product lines.
वित्तीय स्वास्थ्य
The company reported revenue of $27.47M over the trailing twelve months, accompanied by a net income of $-26,602,000 and an EBITDA of $-25,563,000, which reveals a substantial gap between top-line sales and bottom-line profitability indicative of a heavy cost structure associated with clinical development and operational expenses. Free cash flow stands at $-9,951,750, indicating that the company is currently burning cash to fund its operations and R&D efforts rather than generating surplus liquidity for debt repayment or shareholder returns. The gross margin is reported as -26.9%, a negative figure that suggests the cost of goods sold exceeds the revenue generated from sales, a common characteristic in the early clinical phases of biotechnology where manufacturing costs for clinical trials are high before commercial production scales. Operating margin stands at 8.9%, which contrasts sharply with the profit margin of -96.9%, illustrating that while core operations might show some efficiency, the overall profitability is severely eroded by non-operating expenses or significant research and development costs not captured in the operating calculation. In terms of solvency, the company holds $28.23M in cash against $4.20M in debt, resulting in a debt-to-equity ratio of 15.88, which presents a leveraged balance sheet profile given the high leverage ratio despite the positive absolute cash position. The current ratio is 2.74, indicating a robust short-term liquidity position where current assets are more than two and a half times the current liabilities, providing ample buffer for meeting immediate financial obligations. Return on Equity is -121.1% and Return on Assets is -44.6%, metrics that reveal that management has not yet been effective in generating positive returns on the capital invested in the business, reflecting the inherent risks and capital intensity of the clinical-stage biotechnology model.
मूल्यांकन आकलन
The trailing P/E ratio is not available (N/A) due to negative earnings, while the forward P/E is -0.61, implying that the market prices the stock based on expected future earnings that are currently projected to remain negative or that valuation models rely on alternative metrics. The price-to-book ratio is 1.07, indicating that the market values the company at a slight premium over its book value, suggesting investors place some value on the intangible assets and pipeline potential beyond the recorded net assets. The price-to-sales ratio is 1.04, and the EV/EBITDA is -0.18, which suggests that the market is valuing the company primarily on its revenue generation capabilities rather than earnings power, a typical valuation approach for pre-revenue or loss-making biotech firms. The stock has a 52-week high of $1.03 and a 52-week low of $0.17, meaning the current trading price sits within a range where the upper bound represents a significant gain over the lower bound, highlighting the extreme volatility inherent in small-cap biotechnology stocks. The beta value is 1.58, which means the stock is expected to be 58% more volatile than the broader market, indicating that price fluctuations will likely exceed those of large-cap indices during periods of market stress or rally.
Growth & Income
Revenue growth year-over-year is recorded at an impressive 1292.3%, while earnings growth is not applicable (N/A) due to the company's net losses, implying that the expansion of revenue is not yet translating into profitability and that earnings are growing slower than revenue in a negative sense. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that the company reinvests all available earnings, or rather all available cash flow, back into research and development and operational growth rather than distributing income to shareholders. The overall growth and income profile is characterized by explosive revenue expansion coupled with significant cash consumption and a lack of dividend income, typical of a clinical-stage biopharmaceutical company focused on pipeline advancement.